AI is similar to the RDA, which is a daily intake level thought to meet the requirements of 97.5% of people, but AI is based on weaker evidence than RDA
placebo on the time to occurrence of a composite cardiovascular outcome (nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, hospitalization or urgent visit due to heart failure) and a composite renal outcome (end-stage kidney disease, 40% sustained decline in eGFR, cardiovascular death or renal death) in 10,000 individuals with atherosclerotic cardiovascular disease and/or CKD
When compounds are injected intramuscularly, they're rapidly taken up by these blood vessels, leading to faster peak concentrations compared to subcutaneous administration
Alia Crum, Associate (tenured) Professor of Psychology at Stanford University and Director of the Stanford Mind & Body Lab